1)Yasuda M, Kiyohara Y, Arakawa S et al:Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population:the Hisayama study. Invest Ophthalmol Vis Sci 51:3205-3209, 2010
2)Lim LL, Cheung N, Wang JJ et al:Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol 92:1316-1319, 2008
3)Liu W, Xu L, Jonas JB:Vein occlusion in Chinese subjects. Ophthalmology 114:1795-1796, 2007
4)Mitchell P, Smith W, Chang A:Prevalence and associations of retinal vein occlusion in Australia. Arch Ophthalmol 114:1243-1247, 1996
5)The Central Vein Occlusion Study Group:Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. M report. Ophthalmology 102:1425-1433, 1995
6)Ip MS, Scott IU, van Veldhuisen PC et al:A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion:the Standard Care vs Corticosteroid for Retinal Vein Occlusion(SCORE)study report 5. Ophthalmology 127:1101-1014, 2009
7)Rosenfeld PJ, Fung AE, Puliafito CA:Optical coherence tomography findings after an intravitreal injection of bevacizumab(Avastin)for macular edema from central vein occlusion. Ophthalmic Surg Lasers Imaging 36:336-339, 2005
8)川上摂子・若林美宏・村松大弐・他:網膜中心静脈閉塞症の黄斑浮腫に対するベバシズマブ硝子体注射の長期予後にかかわる因子.臨眼 67:1119-1123,2013
9)川上摂子・若林美宏・片井直達・他:網膜中心静脈閉塞症に対するベバシズマブ硝子体内投与.臨眼 64:1183-1186,2010
10)川上摂子・若林美宏・村松大弐・他:木網膜中心静脈閉塞症の黄斑浮腫に対するベバシズマブ硝子体注射の長期予後にかかわる因子.臨眼 67:1119-1123,2013
11)Brown DM, Campochiaro PA, Rishi P et al:Ranibizumab for macular edema following central retinal vein occlusion. Ophthalmology 117:1124-1133, 2010
12)Campochiaro PA, Brown DM, Awh CC et al:Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion:twelve-month outcomes of a phase Ⅲ study. Ophthalmology 118:2041-2049, 2011